TriangleThiotepa (NCT02605421)
Thiotepa trial for Neuroblastoma (NCT02605421). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients diagnosed before age 30 with high-risk neuroblastoma who completed induction chemotherapy without progression. Blood counts must recover, and enough of their own blood stem cells must already be stored.
The idea: give thiotepa and cyclophosphamide, then a second course of melphalan, etoposide and carboplatin. Thiotepa damages DNA and interferes with cell division. Each intensive course is followed by stored stem-cell infusion and growth-factor support. Researchers track progression-free survival.
This phase 2 study plans 12 patients. Minnesota's Masonic Cancer Center in Minneapolis lists the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.